Abstract
Glioblastoma (GBM) is the most common malignant tumor of the central nervous system with poor prognosis. Although the field of immunotherapy in glioma is developing rapidly, glioblastoma is still prone to recurrence under strong immune intervention. The major challenges in the process of immunotherapy are evaluating the curative effect, accurately distinguishing between treatment-related reactions and tumor recurrence, and providing guidance for clinical decision-making. Since conventional magnetic resonance imaging (MRI) is usually difficult to distinguish between pseudoprogression and true tumor progression, many studies have used various advanced imaging techniques to evaluate treatment-related responses. Meanwhile, criteria for efficacy evaluation of immunotherapy are constantly updated and improved. A standard imaging scheme to evaluate immunotherapeutic response will benefit patients finally. This review mainly summarizes the application status and future trend of several advanced imaging techniques in evaluating the efficacy of GBM immunotherapy.
Introduction: The Pseudoprogression Dilemma
Glioblastoma (GBM) remains one of the most aggressive and difficult-to-treat cancers. While the advent of immunotherapy—including dendritic cell (DC) vaccines and immune checkpoint inhibitors (ICIs)—offers new hope, it has introduced a significant diagnostic hurdle: pseudoprogression (PsP).
Pseudoprogression occurs when the immune system successfully infiltrates the tumor site, causing inflammation, edema, and a breakdown of the blood-brain barrier. On standard structural MRI, this inflammatory response appears as increased contrast enhancement, which is virtually indistinguishable from a growing tumor. Misidentifying PsP as true progression can lead to the premature termination of effective treatments, while missing a true recurrence is fatal.
Advanced Imaging Modalities
To solve this identity crisis, researchers have turned to advanced neuroimaging techniques that look beyond simple anatomy to assess the physiological and metabolic state of the lesion.
- Perfusion-Weighted Imaging (PWI): Techniques such as Dynamic Susceptibility Contrast (DSC) and Dynamic Contrast-Enhanced (DCE) MRI measure blood flow and volume. True tumors typically exhibit neovascularization (new, chaotic blood vessel growth), leading to high relative cerebral blood volume (rCBV), whereas inflammatory PsP generally does not.
- Diffusion-Weighted Imaging (DWI): By measuring the movement of water molecules, DWI can estimate cell density. High-density tumor cells restrict water movement (resulting in low Apparent Diffusion Coefficient or ADC values), while the "watery" inflammation of PsP allows for freer diffusion (high ADC values).
- Magnetic Resonance Spectroscopy (MRS): This modality measures chemical metabolites. A high ratio of Choline (indicating cell membrane turnover) to N-acetylaspartate (NAA, indicating neuronal integrity) is a hallmark of tumor recurrence.
- Positron Emission Tomography (PET): Using amino acid tracers like $^{18}$F-FET, PET monitors metabolic activity. Tumors show high amino acid uptake, whereas inflammatory cells typically show different, less intense patterns.
- Amide Proton Transfer (APT): A molecular MRI technique that detects protein and peptide concentrations, which are significantly higher in active tumors than in inflammatory sites.
Clinical Insights and Evaluation Criteria
The review highlights that absolute imaging values are often unreliable due to patient variability. Instead, relative metrics—such as comparing the blood volume of a suspicious area to healthy brain tissue—provide more consistent diagnostic power.
Furthermore, the timing of imaging is critical. The iRANO (immunotherapy Response Assessment in Neuro-Oncology) criteria suggest a 6-month window after starting immunotherapy where any apparent "progression" on imaging should be interpreted with extreme caution, as PsP is most prevalent during this initial phase. The most robust clinical assessments currently come from multi-modal fusion, such as PET/MRI, which combines anatomical detail with metabolic data.
Performance Metrics
Meta-analyses of these technologies reveal varying degrees of accuracy:
- MRS demonstrated some of the highest diagnostic accuracy, with a sensitivity of 91% and specificity of 95%.
- DSC-MRI (Perfusion) remains the most common clinical tool, with a sensitivity of 87% and specificity of 86%.
- DCE-MRI has shown even higher sensitivity in specific studies, reaching up to 92%.
- Amino Acid PET ($^{18}$F-FET) was found to be significantly more accurate than standard MRI for monitoring patients receiving DC vaccinations.
Challenges and Future Directions
Despite these advancements, several hurdles remain. There is a significant lack of standardization across different scanners and software, making it difficult to establish universal diagnostic thresholds. Additionally, many advanced techniques like APT have only been validated in small, single-center studies.
Artificial Intelligence (AI) and radiomics offer a promising path forward. By extracting thousands of sub-visual features from imaging data, machine learning models can identify subtle textures that distinguish a responding immune system from a resurgent tumor. However, these "black box" models require massive, unified datasets to reach clinical-grade reliability.
Conclusion
Accurately differentiating pseudoprogression from tumor recurrence is essential for the successful management of glioblastoma in the era of immunotherapy. While advanced imaging techniques like PWI, DWI, and PET provide superior diagnostic clarity over standard MRI, the future of neuro-oncology lies in the standardization of these protocols and the integration of AI-driven multi-modal analysis in large-scale clinical trials.
Summary updated